Eterna Therapeutics Net Profit Margin Over Time
| ERNA Stock | USD 0.25 0.02 7.41% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Eterna Therapeutics Performance and Eterna Therapeutics Correlation. Eterna |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Profit Margin Analysis
Compare Eterna Therapeutics and related stocks such as Arcus Biosciences, Cullinan Oncology LLC, and Annexon Net Profit Margin Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCUS | (37.5669) | (37.5669) | (37.5669) | (37.5669) | (37.5669) | (37.5669) | (37.5669) | (37.5669) | (5.9373) | (5.0621) | (1.5052) | 0.1384 | (2.3839) | (2.6239) | (2.76) |
| CGEM | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.4335) | (3.09) | (3.24) |
| ANNX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| GPCR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| RLAY | (0.593) | (0.593) | (0.593) | (0.593) | (0.593) | (0.593) | (0.593) | (0.593) | (0.593) | (0.593) | (0.593) | (164) | (184) | (13.3866) | (14.06) |
| REVB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ZURA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PHIO | (133) | (133) | (133) | (52.4436) | (124) | (301) | (473) | (830) | (53.3333) | (53.3333) | (53.3333) | (53.3333) | (53.3333) | (61.33) | (64.4) |
| ZVSA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| DAWN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ABOS | (4.6329) | (4.6329) | (4.6329) | (4.6329) | (4.6329) | (4.6329) | (4.6329) | (4.6329) | (4.6329) | (4.6329) | (5.1003) | (5.1003) | (5.1003) | (5.87) | (6.16) |
| XFOR | (12.2917) | (12.2917) | (12.2917) | (12.2917) | (12.2917) | (12.2917) | (12.2917) | (12.2917) | (12.2917) | (20.7103) | (20.7103) | (20.7103) | (20.7103) | (23.82) | (25.01) |
| INZY | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| PALI | (5.3422) | (32.0474) | (24.8254) | (180) | (1.2 K) | (2 K) | (1.3 K) | (60.2538) | (18.9408) | (543) | (782) | (49.2) | (49.2) | (56.58) | (59.41) |
| UNCY | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (18.9947) | (45.2504) | (47.51) |
| IMMX | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0919 | 0.0827 | 0.0735 |
| APLS | (1.3759) | (1.3759) | (1.3759) | (1.3759) | (1.3759) | (1.3759) | (1.3759) | (1.3759) | (1.3759) | (1.3759) | (1.3759) | (11.2127) | (8.647) | (1.3329) | (1.4) |
| ITOS | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.6222 | 0.3611 | (8.9434) | (8.5) |
| TCRX | (23.9825) | (23.9825) | (23.9825) | (23.9825) | (23.9825) | (23.9825) | (23.9825) | (23.9825) | (23.9825) | (23.9825) | (23.9825) | (4.7949) | (4.8619) | (4.2386) | (4.45) |
Eterna Therapeutics and related stocks such as Arcus Biosciences, Cullinan Oncology LLC, and Annexon Net Profit Margin description
The percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue.My Equities
My Current Equities and Potential Positions
| Eterna Therapeutics | ERNA |
| Classification | Computers |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.25
Check out Eterna Therapeutics Performance and Eterna Therapeutics Correlation. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Eterna Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.